Sandoz

ZARXIO

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / ZARXIO – Q5101

Manufacturer:

Sandoz

Name:

ZARXIO

HCPCS Code Descriptor:

Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram

Category:

Q Code

HCPCS:

Q5101

NDC(s):

61314-0326-10, 61314-0318-01, 61314-0318-10, 61314-0326-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic Status:

Single-Source

Route of Administration:

Injection

About:

ZARXIO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Injection route of administration. The Q Code: Q5101 is aligned to the drug ZARXIO.

Zarxio (filgrastim) is an artificial version of a natural substance that is made in your body and is used to aid the production of white blood cells. Zarxio is administered via subcutaneous injection or an intravenous infusion for roughly 15 to 30 minutes. Zarxio is a biosimilar to its reference product Neupogen (J1442). Patient assistance programs for this medication are offered through Sandoz.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/15

HCPCS Effective Date:

1/1/23

HCPCS Short Description:

Injection, zarxio

Billing and Coding Guide:

https://www.zarxio.com/hcp/billing-and-coding

Patient Assistance:

https://www.zarxio.com/patient/support-services

ZARXIO - Q5101